Abstract Number: 1504 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Background/Purpose Adalimumab is a recombinant IgG1 monoclonal antibody that binds to TNFα blocking its interaction with p55 and p75 cell surface receptors. ABP 501 is…Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…Abstract Number: 562 • 2014 ACR/ARHP Annual Meeting
Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy
Background/Purpose: Adalimumab (ADA) has been previously shown to be effective for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) patients (pts) in the ABILITY-1 trial.1 Week…Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…Abstract Number: 561 • 2014 ACR/ARHP Annual Meeting
A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis
Background/Purpose: We assessed the discriminatory aspects of disease activity measures and response criteria between adalimumab (ADA) and placebo (PBO) in 2 studies of patients (pts)…Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting
Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 17
- Next Page »